Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

CONTEXT Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign from malignant tumors. OBJECTIVE The aim was to determine whether primary tumor location and size are associated with malignancy and decreased survival. DESIGN AND SETTING We performed a retrospective chart review of patients with either pheochromocytoma or sympathetic paraganglioma. PATIENTS The study group comprised 371 patients. MAIN OUTCOME MEASURES Overall survival and disease-specific survival were analyzed according to tumor size and location. RESULTS Sixty percent of patients with sympathetic paragangliomas and 25% of patients with pheochromocytomas had metastatic disease. Metastasis was more commonly associated with primary tumors located in the mediastinum (69%) and the infradiaphragmatic paraaortic area, including the organ of Zuckerkandl (66%). The primary tumor was larger in patients with metastases than in patients without metastatic disease (P < 0.0001). Patients with sympathetic paragangliomas had a shorter overall survival than patients with pheochromocytomas (P < 0.0001); increased tumor size was associated with shorter overall survival (P < 0.001). Patients with sympathetic paragangliomas were twice as likely to die of disease than patients with pheochromocytomas (hazard ratio = 1.93; 95% confidence interval = 1.20-3.12; P = 0.007). As per multivariate analysis, the location of the primary tumor was a stronger predictor of metastases than was the size of the primary tumor. CONCLUSIONS The size and location of the primary tumor were significant clinical risk factors for metastasis and decreased overall survival duration. These findings delineate the follow-up and treatment for these tumors.

[1]  Kendall W. Cradic,et al.  Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. , 2010, Endocrine-related cancer.

[2]  P. Bénit,et al.  SDHA is a tumor suppressor gene causing paraganglioma. , 2010, Human molecular genetics.

[3]  M. Vezeridis,et al.  Laparoscopic adrenalectomy: Balancing the operative indications with the technical advances , 2010, Journal of surgical oncology.

[4]  R. Heshmat,et al.  Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. , 2010, Pathology, research and practice.

[5]  C. Cremers,et al.  SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. , 2010, The Lancet. Oncology.

[6]  Patricia L. M. Dahia,et al.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.

[7]  M. Kupferman,et al.  Paraganglioma syndrome type 1 in a patient with Carney–Stratakis syndrome , 2010, Nature Reviews Endocrinology.

[8]  Steven P. Gygi,et al.  SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma , 2009, Science.

[9]  K. Takano,et al.  Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  M. Rothmund,et al.  Mutations and polymorphisms in the SDHB, SDHD, VHL, and RET genes in sporadic and familial pheochromocytomas , 2009, Endocrine.

[11]  C. Aggeli,et al.  Laparoscopic Surgery for Malignant Adrenal Tumors , 2009, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[12]  E. Baudin,et al.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[13]  A. Grossman,et al.  The diagnosis and management of malignant phaeochromocytoma and paraganglioma. , 2007, Endocrine-related cancer.

[14]  J. Romijn,et al.  Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  K. Pacak,et al.  Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  G. Stamp,et al.  Expression of HIF-1α, HIF-2α (EPAS1), and Their Target Genes in Paraganglioma and Pheochromocytoma with VHL and SDH Mutations , 2006 .

[17]  W. Linehan,et al.  High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  A. Gimenez-Roqueplo.  New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes , 2006, Annals of the New York Academy of Sciences.

[19]  A. Arnold,et al.  Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? , 2006, The Journal of clinical endocrinology and metabolism.

[20]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  S. Richard,et al.  Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Peter Devilee,et al.  The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency , 2005, BMC Medical Genetics.

[23]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[24]  Q. Duh,et al.  Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. , 2004, Surgery.

[25]  David I. Smith,et al.  Malignant pheochromocytoma: current status and initiatives for future progress. , 2004, Endocrine-related cancer.

[26]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[27]  M. Dietel,et al.  Effect of Follicular Cells on Calcitonin Gene Expression in Thyroid Parafollicular Cells in Cell Culture , 1999, The Histochemical Journal.

[28]  D. Farley,et al.  Laparoscopic adrenalectomy for pheochromocytoma. , 2003, Mayo Clinic proceedings.

[29]  B. Baysal.  On the association of succinate dehydrogenase mutations with hereditary paraganglioma , 2003, Trends in Endocrinology & Metabolism.

[30]  P. Rustin,et al.  Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. , 2003, Cancer research.

[31]  U. Müller,et al.  Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC , 2003, Human Genetics.

[32]  Q. Duh,et al.  Laparoscopic Adrenalectomy for Pheochromocytoma , 2002, World Journal of Surgery.

[33]  L. Karnell,et al.  National Cancer Data Base report on malignant paragangliomas of the head and neck , 2002, Cancer.

[34]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[35]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[36]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[37]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[38]  N. Abumrad,et al.  Clinical experience over 48 years with pheochromocytoma. , 1999, Annals of surgery.

[39]  H. Pollard,et al.  Glucocorticoid receptors and regulation of phenylethanolamine-N- methyltransferase activity in cultured chromaffin cells , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  Ober Wb.  Emil Zuckerkandl and his delightful little organ. , 1983 .

[41]  W. Ober.  Emil Zuckerkandl and his delightful little organ. , 1983, Pathology annual.

[42]  R. Wurtman,et al.  Control of enzymatic synthesis of adrenaline in the adrenal medulla by adrenal cortical steroids. , 1966, The Journal of biological chemistry.